Global Thyroid Cancer Drugs Market Report 2021 - Opportunities And Strategies, Market Forecast And Trends

6 Oct, 2021

The thyroid cancer drugs market consists of sales of drugs that are used to treat thyroid cancer. The thyroid tissue is made up of follicular cells and parafollicular cells in which cancer develops. The types of thyroid cancer include follicular, papillary, medullary, anaplastic and thyroid lymphoma.

Global Thyroid Cancer Drugs Market Size And Drivers:

The global thyroid cancer drugs market is expected to grow from $0.4 billion in 2020 to $0.47 billion in 2021 at a compound annual growth rate (CAGR) of 17.5%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $0.98 billion in 2025 at a CAGR of 20.2%. Increasing incidences of thyroid cancer, especially in women is driving the thyroid cancer drugs market.

Request For A Sample For The Global Thyroid Cancer Drugs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2601&type=smp

Trends In The Global Thyroid Cancer Drugs Market

Combination drugs are increasingly being used in the treatment of thyroid cancer as they are more effective and help prevent cancer progression. A combination drug includes two or more active pharmaceutical ingredients (APIs) combined in a single dosage form. These drugs reduce the development of drug resistance and prevent the growth of cancer cells. For instance, the FDA approved the combination of dabrafenib (Tafinlar), a BRAF inhibitor, and trametinib (Mekinist), a MEK inhibitor for the treatment of anaplastic thyroid cancer.

Global Thyroid Cancer Drugs Market Segments:
The global thyroid cancer drugs market is further segmented –
By Drug Type: Ipilimumab, Cabozantinib-S-Malate, Caprelsa (Vandetanib), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Nivolumab, Vandetanib, Others
By End Users: Hospitals, Oncology Clinics, Research Organizations, Others
By Type: Radioiodine Ablation, Thyroid Stimulating Hormone (THS) Suppression, Chemotherapy, Targeted Multikinase Therapy, Others
By Geography: The global thyroid cancer drugs market is segmented into North America, South America, Asia-Pacific, Eastern Europe, Western Europe, Middle East and Africa.

Read More On The Report For The Global Thyroid Cancer Drugs Market At:

https://www.thebusinessresearchcompany.com/report/thyroid-cancer-drugs-global-market-report

Thyroid Cancer Drugs Global Market Report 2021 is one of a series of new reports from The Business Research Company that provides thyroid cancer drugs market overviews, analyzes and forecasts market size and growth for the global thyroid cancer drugs market, thyroid cancer drugs market share, thyroid cancer drugs market players, thyroid cancer drugs market segments and geographies, thyroid cancer drugs market’s leading competitors’ revenues, profiles and market shares. The thyroid cancer drugs market report identifies top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.